Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

NCT04683965 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: Pemetrexed
DRUG: TAS-102
DRUG: Bevacizumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]